Relmada Therapeutics, Inc.
Clinical trials sponsored by Relmada Therapeutics, Inc., explained in plain language.
Clinical-stage biopharmaceutical company developing therapies for central nervous system disorders.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Could a new drug offer hope for Treatment-Resistant depression?
Disease control NO_LONGER_AVAILABLEThis program provides access to esmethadone (REL-1017), an experimental drug, for people with serious depression who have not responded to standard treatments and cannot join other clinical trials. The goal is to offer a potential treatment option when no satisfactory alternative…
Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Bladder cancer drug trial pulled before it even started
Disease control TerminatedThis was a planned Phase 3 study testing NDV-01, a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder, for people with a type of bladder cancer that did not respond to BCG therapy. The trial was withdrawn before enrolling any partici…
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Bladder cancer drug trial pulled before it even started
Disease control TerminatedThis was a planned Phase 3 study comparing a new drug, NDV-01 (a combination of two chemotherapy drugs), against simple observation in people with intermediate-risk non-muscle invasive bladder cancer. The goal was to see if the drug could prevent the cancer from coming back after…
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC